ELTP News and Press, Elite Pharmaceuticals Inc. From 12/31/19

Having once traded on the AMEX at $20 per share and viewed as an innovative company with a novel technology designed to aid in developing controlled release and abuse-resistant opioids, the competitive environment dramatically changed for Elite Pharma ( ELTP ). Ultimately, their share price dr...

Elite Pharmaceuticals ( OTCQB:ELTP ) has received FDA approval for a generic version of Shire's Adderall XR, an extended-release mixed salt of a single entity Amphetamine product with strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg tablets. More news on: Elite Pharmaceuticals, I...

NORTHVALE, NJ / ACCESSWIRE / December 12, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing its own generic products, partnered generic products and proprietary abuse-deterrent opioids, today announced that it received a...

It has long been said, and as history proves, bad things happen to good people. And it follows that bad things happen to good companies. Good companies fail. Evidence? How about a quick comparison of the Fortune 25 for the year 2000 to that for the year 2019 finds only 8 companies from the 2...

Elite Pharmaceuticals, Inc. (ELTP) Q2 2020 Earnings Conference Call November 13, 2019 11:00 AM ET Company Participants Nasrat Hakim - President & Chief Executive Officer Carter Ward - Chief Financial Officer Conference Call Participants Presentation Operator Good ...

Conference Call Scheduled for Wednesday, November 13th at 11:00 AM EST NORTHVALE, NJ / ACCESSWIRE / November 12, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, ...

Financials for Second Quarter Fiscal Year 2020 Ended September 30, 2019 will be released November 12, 2019 NORTHVALE, NJ / ACCESSWIRE / November 6, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of a...

NORTHVALE, NJ / ACCESSWIRE / September 12, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB:ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it received approval from the US Food and Drug A...

Elite Pharmaceuticals, Inc. (ELTP) Q1 2020 Earnings Conference Call Aug 12, 2019 11:30 AM ET Company Participants Nasrat Hakim - President and Chief Executive Officer Carter Ward - Chief Financial Officer Conference Call Participants Presentation Operator Good morning...

Elite Pharmaceuticals ( OTCQB:ELTP ): Q1 GAAP EPS of $0.00. Revenue of $3.36M (+54.8% Y/Y) Press Release More news on: Elite Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,